Anti-Ranibizumab Neutralizing Antibody ELISA kit

Catalog No.

KAD12651

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

15.625-1,000 ng/ml

Precision

CV<20%

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Alternative Names

Fab-12 variant Y0317,RhuFab, CAS: 347396-82-1

Targeting VEGF With 99mTc-Labeled Ranibizumab for Noninvasive Diagnosis of Non-Small Cell Lung Cancer., PMID:40444333

DNA Framework-Enabled Ocular Barrier Penetration for Microinvasive Antiangiogenic Therapy., PMID:39979822

Analysis of ocular fluid in patients with ranibizumab-recalcitrant neovascular age-related macular degeneration who have serum anti-ranibizumab antibodies., PMID:37318582

Intraocular neutralizing antibodies against aflibercept in patients with age related macular degeneration., PMID:36627583

Creation of Retinal Vein Occlusion Model in Cynomolgus Monkeys and Determination of its Pathological Features., PMID:32867658

Adventitial fibroblast-derived vascular endothelial growth factor promotes vasa vasorum-associated neointima formation and macrophage recruitment., PMID:31241138

Important Metabolites in Maintaining Folate Cycle, Homocysteine, and Polyamine Metabolism Associated with Ranibizumab Treatment in Cultured Human Tenon's Fibroblasts., PMID:31234474

Three-Dimensional Transport Model for Intravitreal and Suprachoroidal Drug Injection., PMID:30383198

Phase 2a Randomized Clinical Trial: Safety and Post Hoc Analysis of Subretinal rAAV.sFLT-1 for Wet Age-related Macular Degeneration., PMID:27865764

Anti-VEGFs hinder bone healing and implant osseointegration in rat tibiae., PMID:26073407

Angiogenic potential of vitreous from Proliferative Diabetic Retinopathy and Eales' Disease patients., PMID:25310689

Regression of choroidal neovascularization results in macular atrophy in anti-vascular endothelial growth factor-treated eyes., PMID:25217857

A novel ex vivo murine retina angiogenesis (EMRA) assay., PMID:23631846

In vitro effects of antivascular endothelial growth factors on cultured human trabecular meshwork cells., PMID:20164801

Minimal effects of VEGF and anti-VEGF drugs on the permeability or selectivity of RPE tight junctions., PMID:20042644

[VEGF inhibitors in ophthalmology]., PMID:19642468

Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways., PMID:18441313

A potential therapeutic strategy for inhibition of corneal neovascularization with new anti-VEGF agents., PMID:17107753

Document Download

Anti-Ranibizumab Neutralizing Antibody ELISA kit.pdf